Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
1.
Indian J Pediatr ; 2009 Nov; 76(11): 1161-1163
Article Dans Anglais | IMSEAR | ID: sea-142430

Résumé

We report a child with acute lymphoblastic leukemia who developed primary cutaneous mucormycosis at the site of lumbar puncture during induction chemotherapy. Though high mortality rates are reported with invasive mucormycosis, prompt biopsy, early identification and antifungal therapy using a combination regime of amphotericin-B and rifampicin along with extensive surgical debridement led to complete cure of the lesions in the index case.


Sujets)
Amphotéricine B/usage thérapeutique , Antibactériens/usage thérapeutique , Antinéoplasiques/effets indésirables , Antinéoplasiques/usage thérapeutique , Enfant d'âge préscolaire , Humains , Mâle , Mucormycose/induit chimiquement , Mucormycose/traitement médicamenteux , Leucémie-lymphome lymphoblastique à précurseurs B et T/traitement médicamenteux , Maladies de la peau/induit chimiquement , Maladies de la peau/traitement médicamenteux
2.
Gac. méd. Méx ; 145(3): 235-238, mayo-jun. 2009. ilus, tab
Article Dans Espagnol | LILACS | ID: lil-567448

Résumé

La agranulocitosis es una complicación poco frecuente de los medicamentos antitiroideos, se presenta en menos de 0.5% de los pacientes en los primeros meses de tratamiento. Se considera el efecto adverso más grave de estos medicamentos, ya que se puede complicar con infecciones severas con una tasa alta de mortalidad. La mucormicosis es una infección micótica severa observada en huéspedes inmunocomprometidos como pacientes con diabetes, neoplasias hematológicas o con tratamiento inmunosupresor; sin embargo, la asociación de mucormicosis con agranulocitosis por metimazol no se ha reseñado previamente. El objetivo de este informe es analizar el caso de una mujer con bocio tóxico difuso y agranulocitosis asociada a metimazol, quien desarrolló mucormicosis rinopalatina.


Agranulocytosis is a rare side effect of antithyroid drugs, it occurs in less than 0.5% of patients, usually during the first few months of treatment. It is considered to be the most serious adverse effect of these medications since it may be complicated by serious, life-threatening infections. Mucormycosis is a severe mycotic infection that usually develops in immunocompromised hosts, such aspatients with diabetes mellitus, hematologic malignancies or immunosuppressive therapy. The association of mucormycosis with methimazole-induced agranulocytosis has not been previously described. The objective of this case presentation is to analyze the case ofa woman with diffuse toxic goiter and methimazole-induced agranulocytosis who developed rhino-palatal mucormycosis.


Sujets)
Humains , Femelle , Adulte , Antithyroïdiens , Agranulocytose/induit chimiquement , Thiamazol/effets indésirables , Mucormycose/induit chimiquement
SÉLECTION CITATIONS
Détails de la recherche